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ment and quality of life in Japanese gastroesophageal reflux
disease patients with PPI. Eighty one patients with reflux and
dyspeptic symptom were enrolled. The evaluation of the symptom
was used he Frequency Scale for the Symptom of GERD in 3
categories: total score of 12 questions, score related to reflux
symptoms, and score related to dyspeptic symptoms and the
evaluation of the quality of life was use the 8-item Short Form
Health Survey in 2 categories, the physical component summary
score and mental component summary score. All patients admin-
istered rabeprazole 10 mg/day for 8 weeks. We investigated the
correlation between symptomatic improvement with proton pump
inhibitor and quality of life. Significant symptomatic improvement
was seen in the total score of 12 questions (26.7 ± 8.8 → 17.5 ±
5.9,  p<0.0001), score related to reflux symptoms (14.9 ± 5.4 →
9.6 ± 3.6,  p<0.0001), and score related to dyspeptic symptoms
(11.8 ± 4.3 → 8.0 ± 2.9,  p<0.0001). Significant improvement in
quality of life was seen in the physical component summary
score (47.8 ± 6.6 → 50.0 ± 5.9, p = 0.0209) and mental component
summary score (47.4 ± 8.5 → 50.4 ± 5.3,  p = 0.0133) with proton
pump inhibitor. With proton pump inhibitor, a significant positive
correlation was seen between the improvement rates in total score
of 12 questions, score related to dyspeptic symptoms and in
mental component summary score at 8 weeks (total score of 12
questions:  r = 0.275,  p = 0.0265, score related to dyspeptic
symptoms: r = 0.367, p = 0.0027). In conclusion, quality of life was
associated with improvement in dyspeptic symptoms with proton
pump inhibitor treatment.
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Introduction The ultimate aims of pharmacological management for gastro-
esophageal reflux disease (GERD) are rapid symptomatic
control and improved quality of life (QOL).(1) The results of
rapid symptomatic resolution of symptoms with pharmacological
management achieve greater improvements in QOL.(2) Accord-
ingly, rapid symptomatic control is important in the treatment of
GERD. For non-erosive reflux disease (NERD), symptom resolu-
tion within 7 days after proton pump inhibitor (PPI) treatment has
been reported to correlate with the rate of symptom resolution 4
weeks later.(3) For reflux esophagitis (RE), symptom resolution on
the first day after PPI treatment has been reported to correlate with
the rate of symptom resolution 4 weeks later.(4) On the other hand,
for functional dyspepsia (FD)(5) and uninvestigated dyspepsia,(6)
the symptom resolution rate or symptomatic improvement rate
after 1 week of PPI treatment reportedly do not fully predict the
degree of symptomatic improvement 4 or 8 weeks later. These
studies have been conducted with Western patients, however, and
very few studies have examined the relationship between sympto-
matic improvement and QOL in Japanese GERD patients. In
this study, we investigated the correlation between symptomatic
improvement and QOL in Japanese GERD patients with PPI.
Methods
Patients. Eighty one Japanese outpatients with reflux and
dyspeptic symptoms were enrolled between March 2008 and
March 2009 (Table 1). Inclusion criteria were 20 years or older
and willingness to informed consent. Patients were excluded if
they had the history of gastric and duodenal ulcer, cancer and
esophageal structure.
Symptom assessment. The reflux symptom defined as
heartburn and acid regurgitation and the dyspeptic symptom
defined as postprandial fullness and early satiation, mainly. These
symptoms were evaluated using the Frequency Scale for the
Symptom of GERD (FSSG), a questionnaire developed for use
with Japanese patients(7) (Fig. 1). The questions of FSSG are
related to the 12 symptoms that Japanese patients with GERD
complain of most often, not only ‘heartburn’ and ‘regurgitation’,
but also dyspeptic symptoms such as ‘heavy stomach’ and ‘feeling
full quickly’.(8) The FSSG is designed to score the frequency at
which patients experience symptoms, and has been shown to be
useful in the diagnosis of GERD,(9) assessment of response to
GERD therapy(10) and prediction of optimum treatment.(11)
The FSSG was devised from these 12 questions, which were
scored to indicate the frequency of symptoms, as follows: never/0;
occasionally/1; sometimes/2; often/3; and always/4. The FSSG
was evaluated using the total score (F-TS), the score for the 5
questions concerning acid reﬂux-related symptoms (F-RS), and
for the seven questions concerning dyspeptic symptoms (F-DS) as
indicated in Fig. 1.
QOL assessment. We evaluated QOL in 2 categories, the
physical component summary score (PCS) and mental component
summary score (MCS), using the 8-item Short Form Health
Survey (SF–8TM).(12) The mean scores for the Japanese general
population are 50 points in PCS and MCS scores. A score of <50
thus indicated impaired QOL and the score of ≥50 is considered
to indicate the improved QOL.
Endoscopic findings. Endoscopy was underwent at pre-
treatment and evaluated according to 2nd modified Los Angeles
(LA) classification(13,14) (Grade N, no endoscopic mucosal changes;
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Grade M, minimal change; Grade A, one or more mucosal breaks
≤5 mm long that do not extend between the tops of two mucosal
folds; Grade B, one or more mucosal breaks >5 mm long that do
not extend between the tops of two mucosal folds; Grade C, one or
more mucosal breaks that are continuous between the tops of two
or more mucosal folds, but do not involve the entire esophageal
circumference; and Grade D, a mucosal break that involves the
entire esophageal circumference) among the patients who were
able to obtain agreement.
Treatment. All Patients were administered rabeprazole
10 mg/day for 8 weeks, and completed these 2 questionnaires
about their symptoms and QOL at pre-treatment and after 4 and 8
weeks. All the patients had signed an informed consent. Our study
was approved by our hospital Ethics Committee.
Statistical analysis. We investigated the correlation between
reflux and dyspeptic symptoms and QOL at pre-PPI treatment.
And we examine the relation between the improvement rates
in these symptoms and in QOL with PPI. Results are expressed
as mean ± SD. Continuous variables were compared using one-
way factorial analysis of variance (ANOVA), and discontinuous
variables using Fisher’s exact test. Correlations between variables
were examined using Spearman’s correlation coefficient between
ranks. The improvement of F-TS, F-RS and F-DS associated with
improvement of QOL (PCS or MCS scores ≥50) were identified
by univariate logistic regression analysis. Results are presented as
odds ratios with 95% confidence interval (CI). For all analyses,
p<0.05 was considered to signify a significant difference. Statistical
analysis was performed using SPSS ver.19 (Chicago, IL).
Results
Changes in FSSG scores and QOL (PCS and MCS) during
PPI treatment. Significant symptomatic improvement was seen
in the F-TS, F-RS and F-DS at each evaluation point (F-TS: pre
26.7 ± 8.8, 4 weeks 20.1 ± 6.5,  p<0.0001, 8 weeks 17.5 ± 5.9,
p<0.0001; F-RS: pre 14.9 ± 5.4, 4 weeks 11.1 ± 4.0, p<0.0001, 8
weeks 9.6 ± 3.6, p<0.0001; F-DS: pre 11.8 ± 4.3, 4 weeks 9.1 ± 3.2,
p<0.0001, 8 weeks 8.0 ± 2.9,  p<0.0001) (Fig. 2). Significant
improvement in QOL was seen in both the PCS (pre 47.8 ± 6.6, 4
weeks 50.2 ± 5.2, p = 0.0015, 8 weeks 50.0 ± 5.9, p = 0.0209) and
MCS (pre 47.4 ± 8.5, 4 weeks 50.6 ± 5.9, p = 0.0103, 8 weeks
50.4 ± 5.3, p = 0.0133) with treatment (Fig. 3).
Correlation between GERD symptoms and QOL at pre-
treatment. At pre-treatment, QOL correlated negatively with
F-TS (PCS: r = −0.0359,  p = 0.0010; MCS: r = −0.356,  p =
0.0011), F-RS (PCS: r = −0.0273, p = 0.0136, MCS: r = −0.249,
p = 0.0253) and F-DS (PCS: r = −0.398, p = 0.0002; MCS: r =
−0.422, p<0.0001) (Fig. 4).
Correlation between improvements in FSSG scores and
QOL after 8 weeks with PPI treatment. Examination of the
correlation between the improvement rate in FSSG scores and
QOL after 8 weeks of treatment showed a significant positive
correlation was seen between in MCS at 8 weeks and the improve-
ment rates in F-TS (r = 0.275, p = 0.0265) and in F-DS (r = 0.367,
p = 0.0027). However, No significant correlations were seen
between the improvement rate in F-RS and either in PCS or in
MCS (Fig. 5).
Associated with improvement of QOL. By univariate
logistic regression analysis, only improvement of F-SD was
Table 1. Baseline characteristics
*mean ± SD.
RE: Reflux esophagitis. NERD: Non-erosive reflux disease. PCS: physical component summary score. MCS:
mental component summary score.
Age 55.7 ± 14.0
Gender (male/female) 43/38
Height (cm) 163.6 ± 7.8
Weight (kg) 61.3 ± 8.9
BMI (kg/m2)2 2 . 8 ± 2.5
History of GERD
No history 62
Recurrent 10
Known 9
History of anti-acid secretion treatments (number/%) 23/27.4%
Received the life-style modification (number/%) 50/61.7%
Complicated diseases (number/%) 30/37.0%
Endoscopic findings
RE
Grade A 25
Grade B 4
NERD
Grade N 17
Grade M 19
Uninvestigated 16
Symptom score (FSSG)
Total symptom score 26.7 ± 8.8*
Reflux symptom score 14.9 ± 5.4*
Dyspepsia symptom score 11.8 ± 4.3*
QOL score (SF-8)
PCS 47.8 ± 6.6*
MCS 47.4 ± 8.5* J. Clin. Biochem. Nutr. | May 2012 | vol. 50 | no. 3 | 207
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Fig. 1. Frequency Scale for the Symptoms of GERD (FSSG).
Fig. 2. Changes in FSSG score at each time of assessment. Mean ± SD.
FSSG: the Frequency Scale for the Symptom of GERD. *p<0.05 comparison
with Pre treatment.
Fig. 3. Change rates in QOL at each time of assessment. QOL: Quality
of Life. PCS: physical component summary score. MCS: mental component
summary score. *p<0.05 comparison with Pre treatment. Spearman’s
correlation coefficient.doi: 10.3164/jcbn.11-71
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Fig. 4. Correlation of FSSG and QOL at pre-treatment. F-TS: total score of FSSG. F-RS: acid reflux symptoms of FSSG. F-DS: dyspeptic symptoms of
FSSG. QOL: Quality of Life. PCS: physical component summary score. MCS: mental component summary score. Spearman’s correlation coefficient.
Fig. 5. Correlation of the improvements rate of FSSG and QOL after 8 weeks. F-TS: total score of FSSG. F-RS: acid reflux symptoms of FSSG. F-DS:
dyspeptic symptoms of FSSG. QOL: Quality of Life. PCS: physical component summary score. MCS: mental component summary score. Spearman’s
correlation coefficient. J. Clin. Biochem. Nutr. | May 2012 | vol. 50 | no. 3 | 209
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associated with improved MCS. (odds; 1.021, 95% CI; 1.001–
1.041, p = 0.0391) F-TS and F-RS were not significant.
Discussion
From the report by Fujiwara et al.,(15) we know that the inci-
dence of GERD has risen markedly in Japan from 1990 until now.
The reasons for this trend increased gastric acid secretion in the
Japanese population,(16) the reduced prevalence of Helicobacter
pylori infection,(17) and obesity associated with Westernized eating
habits,(18) Untreated GERD impairs QOL more than untreated
angina pectoris or hypertension,(19) and the ultimate aim of GERD
treatment is improved QOL.(1) To reverse this decline in QOL in
patients with GERD, it is important to ameliorate GERD-related
symptoms through treatments that prevent acid reflux.(20) A
number of studies have identified a correlation between QOL and
GERD-related symptoms. Several have indicated that GERD-
related symptoms are the key to QOL, with greater Japan F-scale
and SF-8 Trial (J-FAST) impairment of QOL as the severity of
GERD-related symptoms increases,(21–23) greater impairment of
QOL as the frequency of nocturnal GERD symptoms increases,(24)
a correlation between the frequency of heartburn and regurgitation
and impairment of QOL,(25) and a marked decrease in QOL with 2
or more episodes of heartburn per week.(26)
Our results also showed a negative correlation between the
severity of both reflux and dyspeptic symptoms and QOL at pre-
treatment PPI. The FSSG used in this study scores the frequency
of typical GERD-related symptoms. The FSSG total score of 12
symptoms in Japanese GERD patients can also be subdivided into
a score related to reflux symptoms such as heartburn and regurgi-
tation (F-RS) and a score related to dyspeptic symptoms such as
bloating and fullness (F-DS).(7,8) Greater impairment in QOL prior
to PPI treatment was seen as symptom severity increased, as
evidenced by the F-TS, F-RS and F-DS. Not only was a correla-
tion seen between QOL and acid reflux symptoms, but the severity
of dyspeptic symptoms also impaired QOL. This finding agrees
with previous studies that suggest dyspeptic symptoms impact
adversely on QOL.(27)
We administered rabeprazole 10 mg/day for 8 weeks, resulting
in significant improvements in the F-TS, F-RS and F-DS, as well
as improvement in QOL. Kusano et al.(8) also used the FSSG to
evaluate the efficacy of 8 weeks of treatment with rabeprazole
10 mg/day. As with this study, they found that not only acid reflux
symptoms, but also dyspeptic symptoms were improved, so they
defined dyspeptic symptoms that respond to a PPI as ‘acid related
dyspepsia’.
We also examined the correlation between the improvement
rate in GERD symptoms and in QOL. Earlier studies found a
correlation between the rate of symptom resolution with pharma-
cological management and the improvement rate in QOL,(28) and
showed that complete resolution of symptoms is required to
achieve high improvements in QOL.(21) In our study, a significant
positive correlation was seen between the improved MCS and the
improvement rates in F-TS and F-DS. However, no correlations
were seen between the improvement rate in F-RS and either the
improvement rates in PCS or in MCS. This lack of correlation
between the improvement rate in acid reflux symptoms and in PCS
or MCS is extremely interesting. The reason that the severity of
acid reflux symptoms, typical symptoms of GERD, correlated
with QOL, but in our study, the improvement of reflux symptoms
was not correlated with the improvement of QOL, is unclear.
There is possibility of two reasons. First, the ratio of RE was
low in our study (35.8%). Pooled response rates of PPI were
significantly higher for patients with RE compared with NERD.(29)
There is a possibility that acid reflux symptoms correlates to QOL,
if there are a lot of ratios of RE. Second, it is a difference of the
symptom improvement speed and the QOL improvement speed.
The symptom improvement speed was prompt, and the QOL
improvement speed was slow. Especially, the improvement speed
of acid reflux symptoms was quickly, and the improvement speed
of dyspeptic symptoms was more gradual. The improvement
speed of acid reflux symptoms did not catch up at the QOL
improvement speed for promptness, and the improvement speed
of dyspeptic symptoms caught up oppositely at the QOL improve-
ment speed. In a current report, the symptom resolution within 7
days after PPI treatment has been correlated with the rate of
symptom resolution 4 weeks later, but not with QOL improve-
ment.(3–6) In our study, it is thought that the improvement of
dyspeptic symptoms associated in QOL improvement, impor-
tantly. The resolution rate for heartburn symptoms with PPI treat-
ment is lower in the presence of multiple dyspeptic symptoms.(30)
Consideration of these factors suggests that improvement in
dyspeptic symptoms is a factor that strongly influences improved
QOL with PPI therapy.
Study Limitation
Our study is a single arm open label study without placebo
control.
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Abbreviations
FD functional dyspepsia
F-DS dyspeptic symptoms of FSSG
F-RS acid reﬂux symptoms of FSSG
F-TS total score of FSSG
GERD gastroesophageal reflux disease
MCS mental component summary score
NERD non-erosive reflux disease
PCS physical component summary score
PPI proton pump inhibitor
QOL quality of life
RE reflux esophagitis
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